|Table of Contents|

Analysis of lmmunophenotypes in children and adults with B-cell acute lymphoblastic leukemia

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 02
Page:
289-292
Research Field:
Publishing date:

Info

Title:
Analysis of lmmunophenotypes in children and adults with B-cell acute lymphoblastic leukemia
Author(s):
WANG Xiaohui; CHEN Fang; WANG Shaokun; ZHANG Henan; QUAN Bi; ZHANG Jihong
Hematology Laboratory,Shengjing Hospital of China Medical University,Liaoning Shenyang 110022，China.
Keywords:
B-cell acute lymphoblastic leukemia; children; adults; immunophenotype
PACS:
R733.71
DOI:
10.3969/j.issn.1672-4992.2021.02.023
Abstract:
Objective:To analyze the difference of immunophenotype in B-ALL between children and adults patients and to explore its phenotype characteristics and clinical significance.Methods:Bone marrow samples from 260 children and 111 adults initial B-ALL patients were selected for the study.Flow cytometry was used to detect the immunophenotype and analyze the expression of antigens.Results:B-cell associated antigen CD19,CD22 and CD79a were shown to have higher expression in all B-ALL patients with the rate of 100%,99.73%,99.19%.Antigen for mature B-cell CD20 and cIgM were shown to have lower expression in all B-ALL patients with the rate of 31.27% and 21.29%.CD10 expression was observed in 94.88% B-ALL patients and significantly higher in children compared with adults B-ALL patients (P＜0.05).Stem/progenitor cell marker antigen CD34,HLA-DR,CD38 and cTdT expression were 76.82％,98.38％,98.92％ and 92.72%.CD34 expression was significantly lower in children compared with adults B-ALL patients (P＜0.05).The myeloid antigen CD33,CD13 and CD15 were shown to have higher expression in all B-ALL patients with the rate of 20.49%,20.49% and 7.01%.CD33 and CD15 expression were significantly lower in children compared with adults B-ALL patients (P＜0.05).Conclusion:The immunophenotype played an important role in diagnosis and antibody panel in minimal residual disease detection in children and adults with B-ALL.

References:

［1］ BOULLOSA LF,SAVALIYA P,BONNEY S,et al.Identification of survivin as a promising target for the immunotherapy of adult B- cell acute lymphoblastic leukemia［J］.Oncotarget,2017,9(3):3853-3866.
［2］ KIZILOCAK H,OKCU F.Late effects of therapy in childhood acute lymphoblastic leukemia survivors［J］.Turk J Haematol,2019,36(1):1-11.
［3］ MCGREGOR S,MCNEER J,GURBUXANI S.Beyond the 2008 World Health Organization classification:The role of the hematopathology laboratory in the diagnosis and management of acute lymphoblastic leukemia［J］.Semin Diagn Pathol,2012,29(1):2-11.
［4］ YAO QM,LIU KY,GALE RP,et al.Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia［J］.BMC Cancer,2016,16:269.
［5］ CORRENTE F,BELLESI S,METAFUNI E,et al.Role of flow-cytometric immunophenotyping in prediction of BCR/ABL1 gene rearrangement in adult B - cell acute lymphoblastic leukemia［J］.Cytometry B Clin Cytom,2018,94(3):468-476.
［6］ WU HB,LV WF,WANG YX,et al.BCL6 promotes the methotrexate-resistance by upregulating ZEB1 expression in children with acute B lymphocytic leukemia［J］.Eur Rev Med Pharmacol Sci,2018,22(16):5240-5247.
［7］ KURT H,ZHENG L,KANTARJIAN HM,et al.Secondary philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome［J］.Mod Pathol,2018,31(7):1141-1154.
［8］ JIANG Z,WU D,LIN S,et al.CD34 and CD38 are prognostic biomarkers for acute B lymphoblastic leukemia［J］.Biomark Res,2016,4:23.
［9］ ALVES GV,FERNANDES AL,FREIRE JM,et al.Flow cytometry immunophenotyping evaluation in acute lymphoblastic leukemia:Correlation to factors affecting clinic outcome［J］.J Clin Lab Anal,2012,26(6):431-440.
［10］ AOKI Y,WATANABE T,SAITO Y,et al.Identification of CD34+ and CD34- leukemia - initiating cells in MLL-rearranged human acute lymphoblastic leukemia［J］.Blood,2015,125(6):967-980.
［11］ KIM DY,PARK HS,CHOI EJ,et al.Immunophenotypic markers in adult acute lymphoblastic leukemia:The prognostic significance of CD20 and TdT expression［J］.Blood Res,2015,50(4):227-234.
［12］ THOMAS DA,O'BRIEN S,JORGENSEN JL,et al.Prognostic significance of CD20 expression in adults with de novo precursor B - lineage acute lymphoblastic leukemia［J］.Blood,2009,113(25):6330-6337.
［13］ THOMAS DA,O'BRIEN S,FADERL S,et al.Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia［J］.J Clin Oncol,2010,28(24):3880-3889.
［14］ RAPONI S,DE PROPRIS MS,INTOPPA S,et al.Flow cytometric study of potential target antigens (CD19,CD20,CD22,CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia:Analysis of 552 cases［J］.Leuk Lymphoma,2011,52(6):1098-1107.
［15］ HORTON HM,BERNETT MJ,PONG E,et al.Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia［J］.Cancer Res，2008,68(19):8049-8057.
［16］ FUDA F,CHEN W.Minimal/measurable residual disease detection in acute leukemias by multiparameter flow cytometry［J］.Curr Hematol Malig Rep,2018,13(6):455-466.
［17］ JALAL SD,AL-ALLAWI NAS,AL DOSKI AAS.Immunophenotypic aberrancies in acute lymphoblastic leukemia from 282 Iraqi patients［J］.Int J Lab Hematol,2017,39(6):625-632.
［18］ LAHJOUJI A,BACHIR F,BENNANI S,et al.Clinical importance of myeloid antigen expression in Moroccan patients with adult B - lineage acute lymphoblastic leukemia［J］.Neoplasma,2013,60(5):553-560.
［19］ VITALE A,GUARINI A,ARIOLA C,et al.Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia.Results of the GIMEMA ALL 0496 trial［J］.Haematologica,2007,92(3):342-348.
［20］ RAEISI M,NIKHANFAR AR,NEJATE B,et al.Role of CD135/CD117 on prognosis and overall survival of acute myeloid leukemia［J］.Asian Pac J Cancer Prev,2019,20(9):2625-2631.
［21］ BASTURK A,AKINCI S,HACIBEKIROGLU T,et al.Prognostic significance of flow cytometry findings in Turkish adult acute leukemia patients［J］.Eur Rev Med Pharmacol Sci,2015,19(18):3360-3366.

Memo

Memo:
辽宁省科学技术计划项目（编号：2019JH1/10300005）
Last Update: 1900-01-01